B-CELL NON HODGKIN LYMPHOMA
Clinical trials for B-CELL NON HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL NON HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL NON HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control CompletedThis study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from the blood of adults with certain blood cancers (leukemia and lymphoma) that had come back or not responded to treatment. The main goals were to see if the cells could be succe…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated May 17, 2026 03:08 UTC
-
New combo therapy shows promise for kids with aggressive blood cancers
Disease control CompletedThis study tested whether adding 6 doses of rituximab (a targeted antibody) to standard chemotherapy improves outcomes for 482 children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell leukemia. Participants were aged 6 months to 18 years with high-risk disease. The …
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
Arthritis drug may tame CAR-T's dangerous side effects
Symptom relief CompletedThis study tested whether anakinra, a drug used for rheumatoid arthritis, could prevent two serious side effects of CAR-T cell therapy: cytokine release syndrome (CRS) and nerve damage. 27 adults with B-cell lymphoma received anakinra alongside their CAR-T treatment. The goal was…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated May 13, 2026 16:01 UTC